Role of Endogenous Myoglobin in Anthracycline Response in Breast Cancer
Biomolecules · 18.07.2026 · 16 (7) · 1055
DOI: 10.3390/biom16071055 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, online erschienen am 18.07.2026. Verfasst von Ilona Rybinska und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biotechnology and Translational Medicine, University of Milan, 20133 Milan, Italy. Hauptthemen laut MEDLINE: Myoglobin, Breast Neoplasms, Doxorubicin, Anthracyclines. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Anthracyclines such as doxorubicin (DOX) remain central components of breast cancer (BC) chemotherapy, although their efficacy is frequently limited by drug resistance. Myoglobin (MB), an oxygen-binding heme protein expressed in breast tumors, has been implicated in the detoxification of DOX in cardiomyocytes, but its role in BC remains unclear. Using MB-expressing and MB-knockout (MBKO) MDA-MB-468 BC cells, we demonstrate that MB confers hypoxia-dependent resistance to DOX. Under hypoxia, MB-expressing cells exhibited reduced intracellular DOX-associated fluorescence, enhanced superoxide generation, and decreased sensitivity to DOX, findings consistent with altered redox cycling and oxidative processing of the drug. Re-expression of MB in MBKO cells restored resistance, whereas pharmacological modulation of MB function using carbon monoxide-releasing molecule-3 and tert-butoxycarbonyl-alanine reversed MB-dependent reductions in intracellular DOX accumulation. In contrast, aclarubicin, an anthracycline lacking the hydroquinone moiety required for efficient redox cycling, failed to reproduce MB-dependent effects. Analyses of four independent neoadjuvant BC cohorts further demonstrated that elevated MB expression was consistently associated with reduced probability of achieving pathological complete response following anthracycline-containing chemotherapy. Collectively, these findings identify MB as a previously unrecognized modulator of BC response to redox-active anthracyclines and support its potential utility as both a predictive biomarker and therapeutic target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Biotechnology and Translational Medicine, University of Milan, 20133 Milan, Italy.
- Experimental and Molecular Pediatric Cardiology, German Heart Center, TUM University Hospital, Technical University of Munich, 80636 Munich, Germany.
- Institute of Organismic and Molecular Evolution, Molecular Genetics and Genome Analysis, Johannes Gutenberg University, 55128 Mainz, Germany.
- Department of Veterinary Physiology, University of Zurich, CH-8057 Zurich, Switzerland.
- Department of Biomedical Sciences for Health, University of Milan, 20133 Milan, Italy.
ORCID-Profile: Ilona Rybinska, Thomas A Gorr, Gaetano Cairo
Zitieren
APA
Rybinska, I., Petry, A., Hankeln, T., Gorr, T. A., & Cairo, G. (2026). Role of Endogenous Myoglobin in Anthracycline Response in Breast Cancer. Biomolecules, 16(7), 1055. https://doi.org/10.3390/biom16071055
Vancouver
Rybinska I, Petry A, Hankeln T, Gorr TA, Cairo G. Role of Endogenous Myoglobin in Anthracycline Response in Breast Cancer. Biomolecules. 2026;16(7):1055. doi:10.3390/biom16071055
BibTeX
@article{Rybinska2026,
author = {Rybinska, Ilona and Petry, Andreas and Hankeln, Thomas and Gorr, Thomas A and Cairo, Gaetano},
title = {Role of Endogenous Myoglobin in Anthracycline Response in Breast Cancer},
journal = {Biomolecules},
year = {2026},
volume = {16},
number = {7},
pages = {1055},
doi = {10.3390/biom16071055}
}
EUVIMED